AlphAIAlphAI — Financial news for AI agents
fool.comSEP 82 min read$TDOC

2 Beaten-Down Stocks to Avoid Right Now

Teladoc Health (TDOC) and Recursion Pharmaceuticals (RXRX) face significant challenges. Teladoc's revenue declined 4% YoY to $606.9M, with BetterHelp's revenue and users dropping 12% and 11% YoY, respectively. Recursion, an AI-driven biotech, lacks approved products and has seen its stock fall 21% over the past year. Both companies show dim prospects, according to the analysis.

Original reporting
fool.com
Published Sep 8, 2026, 6:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 6:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
2 Beaten-Down Stocks to Avoid Right Now — source image
Source · fool.com
Decision brief

The 30-second read

$TDOCBearishLow
01

Why it matters

Both companies face structural headwinds; the piece offers no new data beyond existing earnings releases.

02

Market read

Limited trading relevance; primarily a cautionary note rather than a catalyst‑driven move.

03

What to watch

Potential future insurance contracts for Teladoc and undisclosed AI breakthroughs at Recursion could alter outlook.

Relevance 4/10Novelty 2/10Timing: post‑Q2 earnings recap

Background

The article is a recommendation to avoid two heavily beaten‑down healthcare stocks, summarizing recent quarterly performance and strategic challenges.

Company-level read

Ticker impact

$TDOCBearishMedium confidence
Context

Teladoc Health reported a Q2 revenue decline of 4% YoY and a wider loss per share, reinforcing its dim outlook.

Expected impact

Neutral to slightly down as investors may further discount the stock.

Evidence & confidence

The article recaps already‑released earnings without new information, limiting actionable insight.

$RXRXBearishMedium confidence
Context

Recursion Pharmaceuticals disclosed no approved products and no Phase 3 trials, highlighting continued risk after a 21% stock decline over the past year.

Expected impact

Likely flat to down as investors remain skeptical.

Evidence & confidence

The piece repeats known status of the firm without fresh data, offering limited trading impetus.

Market effects

Sector

Reinforces bearish sentiment in the broader telehealth and AI‑biotech subsectors.

Regional

Minimal; effects confined to U.S. healthcare equities.

Global

Limited to investors tracking health‑tech stocks.

Counterpoint

What could challenge this read

Some investors may view the low valuations as a long‑term entry point if turnaround initiatives succeed.

Key entities

  • company
    Teladoc Health

    Telemedicine provider with declining Q2 results.

  • company
    Recursion Pharmaceuticals

    AI‑focused biotech lacking approved products.

Read at source← All news

Related articles

SEP 4
$RXRXMed

RXRX Stock Steadies As AI Drug Engine Tightens Spending

Recursion Pharmaceuticals (RXRX) shares rose 5.81% on AI-driven drug discovery progress. The company reported $74.3M revenue, negative margins, and $545M in cash. Genentech optioned a neuroscience target, and RXRX cut FY26 spending to $375M, extending cash runway to early 2028. Analysts have mixed views, with an average price target of $7.22.

stockstotrade.com3 min
SEP 4
$RXRXMed

RXRX Tightens Cash Burn As AI Drug Pipeline Advances

Recursion Pharmaceuticals (RXRX) stock rose 5.96% on September 4, 2026, to $3.64, driven by AI drug discovery advancements. The company reported Q2 2026 revenue of $7.3M, a net loss of $131M, and $545M in cash. RXRX reduced its FY26 expense guidance to $375M, reflecting tighter cost management. Analysts' average price target is $7.22, with tangible clinical and partnership catalysts on the horizon.

stockstotrade.com4 min
SEP 4
$RXRXMed

RXRX Tightens Costs As AI Drug Pipeline Advances

Recursion Pharmaceuticals Inc. (RXRX) stock rose 5.83% on positive AI drug discovery progress. The company reported Q2 revenue of $74.3M, negative margins, and cash burn of -$106M, but has $545.7M in cash. RXRX guided 2026 cash operating expenses to $375M, down 40% from 2024. Analysts have mixed views, with Morgan Stanley trimming its target to $5.30 but the Street's average at $7.22.

timothysykes.com2 min
SEP 1
$TDOCLow

Teladoc nabs insurance veteran as new CFO

Teladoc Health appointed Michael Grasher as its new CFO, effective immediately. Grasher succeeds Mala Murthy, who left in November. He brings over 30 years of experience in insurance and financial services, most recently as CFO of IFG Companies. The move follows Teladoc's recent revenue guidance reduction, partly due to challenges in its mental health unit, BetterHelp.

yahoo.com2 min
AUG 31
$TDOCMed

Teladoc appoints insurance executive Michael Grasher as CFO

Teladoc Health named Michael Grasher as its new CFO. Grasher, with over 30 years of experience in insurance, previously served as CFO of IFG Companies. The appointment follows Teladoc's recent revenue forecast cut and challenges in its mental health unit, BetterHelp. Analyst Elizabeth Anderson views the move positively for Teladoc's leadership.

wncy.com2 min
AUG 25
$RXRXMed

RXRX Stock Rallies As AI Drug Platform Tightens Cash Burn

Recursion Pharmaceuticals (RXRX) stock rose 7.23% on August 25, 2026, driven by AI-driven drug discovery progress. The company reported Q2 revenue of $7.7M, a net loss of $131M, and holds $545.7M in cash. Analysts have mixed views, with a mean price target of $7.22. RXRX is advancing its pipeline and cut FY26 cash burn guidance to $375M, extending its runway into early 2028.

stockstotrade.com3 min